US-based contract research organisation (CRO) Omnicare Clinical Research has opened two offices in China.
The fully staffed facilities, in Shanghai and Beijing respectively, will house professionals in project management, clinical trial services, regulatory affairs and business development. They formalise what Omnicare Clinical Research says has been a strong presence in China since 2001.
According to president and chief executive officer Dr Dale Evans, the opening of the Shanghai and Beijing offices is “a vital component of our Asia Pacific business strategy”. The region is “a burgeoning centre of drug development that offers numerous advantages”, he added. “We’re committed to the marketplace here and our new offices will help us provide clients with an even greater level of support.”
Omnicare Clinical Research’s other established offices in the Asia Pacific region take in Australia, India, Japan, Singapore and Taiwan.
The Pennsylvania-based CRO is a subsidiary of Omnicare, Inc, which provides pharmacy services to long-term care facilities and other chronic-care settings. Omnicare Clinical Research offers Phase I-IV clinical development support to pharmaceutical, biotechnology and medical device companies from locations in 31 countries worldwide.
In keeping with its parentage, the company is also an industry leader in geriatrics-focused drug trials.
